Mortality reduction in pediatric patients with severe fatal human adenoviral pneumonia treated with high titer neutralizing antibodies (NAbs) plasma: a retrospective cohort study

BACKGROUND: Severe fatal human adenoviral (HAdV) pneumonia is associated with significant mortality and no effective drug is available for clinical therapy. We evaluated the association and safety of high titer neutralizing antibodies (NAbs) plasma in pediatric patients with severe fatal HAdV pneumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Hongyan, Chen, Feiyan, Zuo, Yunlong, Huang, Bolun, Yang, Yiyu, Dang, Run
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938635/
https://www.ncbi.nlm.nih.gov/pubmed/35317780
http://dx.doi.org/10.1186/s12887-022-03225-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938635/
https://www.ncbi.nlm.nih.gov/pubmed/35317780
http://dx.doi.org/10.1186/s12887-022-03225-1

Ejemplares similares